Sales & Marketing Unlocking the potential of connected commercialisation solut... It is no secret that today’s post-pandemic healthcare landscape in the UK is very different to its pre-pandemic counterpart.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.